Compare Ginkgo Bioworks Holdings Inc (DNA) vs Workiva Inc (WK) Price & Performance

Ginkgo Bioworks (DNA) trades at $7.29, down 4.71% with bearish technical signals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, continuing its strategic pivot to autonomous labs. Despite beating EPS expectations in two of the last three quarters, DNA shows negative profitability with -219.6% net income margin and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant institutional selling pressure.

DNA faces substantial execution risk during its business transition, with declining revenue and persistent losses offset by potential in autonomous laboratory technology. The stock's current valuation at 3.61x sales appears stretched given negative earnings, requiring successful operational turnaround for sustainable recovery. Near-term catalysts depend on revenue stabilization and cost management improvements.

WK trades at $67.73, up 0.61% today, near its consensus price target of $69. The stock shows bullish technical signals with strong moving average support and recent earnings beats. Revenue grew to $966 million in 2026 with net income turning positive at $47 million, reflecting improved profitability. Positive sentiment is driven by AI product launches and consistent earnings outperformance.

Outlook remains positive given earnings momentum and AI innovation, but high valuation multiples pose risks. Investors face elevated P/E and EV/EBITDA ratios, requiring sustained growth to justify premiums. Competitive pressures and execution on AI initiatives are key to maintaining upward trajectory amid market volatility.